Clinical trials: Immunotherapy-naive
Urothelial Carcinoma, Bladder Cancer
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Upon successful screening and registration, enrollment to a cohort will begin. If DLT criteria are exceeded in a cohort, that cohort will close and will not proceed to Phase 2 of the study.
- Trial name
- ADAPT-BLADDER (NCT03317158)
- Testing
- Durvalumab (Cohort 1-3), External Beam Radiotherapy (EBRT), Bacillus Calmette-Guérin (BCG)
- Where
- 9 sites in United States
- Volunteers
- 186 people
- Sponsor
- Noah Hahn, M.D.
Prostate Cancer
Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance
This study will evaluate the safety and efficacy of a prostate cancer vaccine named Proscavax (Prostate-specific antigen(PSA) / Interleukin-2(IL-2) / Granulocyte-macrophage colony-stimulating factor(GM-CSF)) in patients with…
- Trial name
- NCT03579654
- Testing
- Proscavax
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- OncBioMune Pharmaceuticals
Pancreatic Cancer Liver Metastases, Immunotherapy-naive
A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.
To evaluate the efficacy of arterial infusion chemotherapy and embolization combined with iparplidutol-volerilis (QL1706) as first-line treatment for pancreatic cancer liver metastases based on progression-free survival (PFS).
- Trial name
- NCT07333287
- Testing
- Interventional, Targeted Therapy (anti-VEGF), Immunotherapy + Targeted Therapy
- Volunteers
- 38 people
- Sponsor
- Shandong Provincial Hospital
Crohn Disease
Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC
The purpose of this study is to assess the safety and effectiveness of three different treatments for patients with Crohns disease who have not responded to previous treatment with a group of drugs commonly used to treat Crohn's…
- Trial name
- NCT00094458
- Testing
- infliximab (IFX) infusion; azathioprine (AZA) caps
- Where
- 115 sites in United States, Austria and 13 more
- Volunteers
- 508 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
HIV Infections
Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults
Effective, suppressive treatment for HIV infected patients can be a major challenge because HIV progressively destroys their immune systems.
- Trial name
- NCT00110578
- Testing
- Adoptive transfer of HIV-specific CD8+ T cells, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
This phase II trial compares the effect of adding proton spatially fractionated radiotherapy (SFRT) or photon stereotactic body radiotherapy (SBRT) to standard immunotherapy pembrolizumab before surgery (neoadjuvant) in treating…
- Conditions
- Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT07783581
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
This phase III trial studies how well nivolumab and ipilimumab works with or without local consolidation therapy in treating patients with stage IV non-small cell lung cancer.
- Conditions
- Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT03391869
- Testing
- Ipilimumab, Local Consolidation Therapy, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 339 people
- Sponsor
- M.D. Anderson Cancer Center
Non-muscle Invasive Bladder Cancer
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.
- Trial name
- NCT02138734
- Testing
- BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation)
- Where
- 108 sites in United States, India and 1 more
- Volunteers
- 369 people
- Sponsor
- ImmunityBio, Inc.
Non-Small Cell Lung Cancer Metastatic
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
Non Small Cell lung cancer (NSCLC) remains the first cause of death by cancer in the World. For the patients presenting a NSCLC stage IV, the median of survival is about 15 months today.
- Trial name
- DICIPLE (NCT03469960)
- Testing
- Ipilimumab, Nivolumab
- Where
- 47 sites in France
- Volunteers
- 265 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Malignant Pleural Mesothelioma
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
This clinical trial will evaluate the safety and immune response of the sequential administration cancer vaccine CRS-207 (with or without cyclophosphamide) followed by standard of care chemotherapy (pemetrexed and cisplatin).
- Trial name
- NCT01675765
- Testing
- Immunotherapy plus chemotherapy, Immunotherapy with cyclophosphamide plus chemotherapy
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Aduro Biotech, Inc.
Non-small Cell Lung Cancer Stage IV
Immunotherapy in Patient With Poor General Condition
Immunotherapeutic approaches targeting immune checkpoint proteins PD-1/PD-L1 have recently demonstrated clinical efficacy in several cancer types, and have changed the therapeutic landscape in metastatic melanoma or non-small…
- Trial name
- SAVIMMUNE (NCT04108026)
- Testing
- Durvalumab
- Where
- 20 sites in France
- Volunteers
- 50 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lymphoma
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00258336
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine, rituximab, sargramostim
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Favrille
Squamous Cell Carcinoma, Urinary Tract Cancer
Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).
Atezolizumab in patients with urinary tract squamous cell carcinoma: a single-arm, open-label, multicentre, phase II clinical trial
- Trial name
- AURORA (NCT05038657)
- Testing
- Atezolizumab
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Stage IV NSCLC
Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients
This pilot phase I trial aims to investigate the safety and tolerability of anti-programmed cell death-1 (PD-1) monoclonal antibody Sintilimab (also called IBI308) in combination with concurrent stereotactic body radiation…
- Trial name
- NCT03812549
- Testing
- Sintilimab, stereotactic body radiation therapy, Low Dose Radiotherapy
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sichuan University
Prostatic Neoplasms, Immunotherapy
Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients
Prostate cancer is the only type of cancer in which conventional dendritic cells (DC) treatment has a beneficial effect on the overall survival.
- Conditions
- Prostatic Neoplasms, Immunotherapy, Dendritic Cells, Vaccines
- Trial name
- NCT02692976
- Testing
- mDC vaccination, pDC vaccination, mDC and pDC vaccination
- Where
- Netherlands
- Volunteers
- 21 people
- Sponsor
- Radboud University Medical Center
Stage IIIB Melanoma, Stage IIIC Melanoma
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
The purpose of this study is to evaluate the efficacy of adjuvant adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin-2 (IL-2) after a nonmyeloablative lymphodepletion (NMA-LD) preparative…
- Conditions
- Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IIID Melanoma
- Trial name
- NCT06190249
- Testing
- LN-144, Cyclophosphamide, Mesna
- Sponsor
- James Isaacs, MD